MedPacto and Theragen Etex have come together to expand the anti-cancer drug business
Apr 10, 2023
-Agreement ceremony on the 10th, cooperating together bringing domestic new drug into the global market while increasing the corporate values
MedPacto(CEO, Seong-jin Kim) and Theragen Etex(CEO, Jin-up Ko, Si-hong Park) announced that they have shaken on to expand the anti-cancer drug business.
MedPacto announced on the 10th that it had signed a business agreement with Theragen Etex to expand its anti-cancer drug business at its headquarters in Seocho-dong, Seoul. Executives from both companies, including the CEO of MedPacto, Seong-jin Kim, and the CEOs of Theragen Etex, Jin-up Ko, and Si-hong Park attended the ceremony.
The agreement ceremony links both the first-in-class anti-cancer drug with commercialization and is expected to strengthen both companies’ business capabilities. The business agreement also expects to enhance both companies’ corporate values while cooperating together bringing domestic new drugs into the global market.
MedPacto, currently developing innovative new drugs including anti-cancer drugs, expects further developments with its new drug candidates under a new business agreement. Theragen Etex expects a strengthening of its competitiveness in the field through expanding its pipelines resulting in expanding its anti-cancer drug business.
“Based on MedPacto’s successful anti-cancer drug development, Theragen Etex has preemptively signed the future growth business agreements with MedPacto to expand and lead the domestic anti-cancer drug market.”, stated Theragen Etex representative.